Triptorelin 3- and 6-month sustained-release formulations in locally advanced or metastatic prostate cancer: a profile of their use in the EU
Authors:
- 2 June 2017
- journal article
- adis drug-q-and-a
- Published by Springer Nature in Drugs & Therapy Perspectives
- Vol. 33 (7) , 321-325
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical TrialJournal of Urology, 2017
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate CancerEuropean Urology, 2017
- Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate CancerAdvances in Therapy, 2016
- An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate CancerAdvances in Therapy, 2016
- Factors predicting progression to castrate‐resistant prostate cancer in patients with advanced prostate cancer receiving long‐term androgen‐deprivation therapyBJU International, 2016
- Evaluation of urinary prostate cancer antigen‐3 ( PCA 3) and
TMPRSS
2‐
ERG
score changes when starting androgen‐deprivation therapy with triptorelin 6‐month formulation in patients with locally advanced and metastatic prostate cancerBJU International, 2014
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012European Journal of Cancer, 2013
- Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfortCancer Management and Research, 2011
- Triptorelin Embonate (6-Month Formulation)Drugs, 2010
- Triptorelin 6-Month Formulation in the Management of Patients with Locally Advanced and Metastatic Prostate CancerClinical Drug Investigation, 2009